POPULARITY
Categories
73 episodes with Targeted therapy
54 episodes with Targeted therapy
37 episodes with Targeted therapy
54 episodes with Targeted therapy
72 episodes with Targeted therapy
46 episodes with Targeted therapy
46 episodes with Targeted therapy
37 episodes with Targeted therapy
60 episodes with Targeted therapy
37 episodes with Targeted therapy
37 episodes with Targeted therapy
14 episodes with Targeted therapy
17 episodes with Targeted therapy
13 episodes with Targeted therapy
38 episodes with Targeted therapy
9 episodes with Targeted therapy
8 episodes with Targeted therapy
11 episodes with Targeted therapy
13 episodes with Targeted therapy
10 episodes with Targeted therapy
8 episodes with Targeted therapy
8 episodes with Targeted therapy
13 episodes with Targeted therapy
7 episodes with Targeted therapy
13 episodes with Targeted therapy
6 episodes with Targeted therapy
6 episodes with Targeted therapy
12 episodes with Targeted therapy
6 episodes with Targeted therapy
5 episodes with Targeted therapy
12 episodes with Targeted therapy
4 episodes with Targeted therapy
7 episodes with Targeted therapy
3 episodes with Targeted therapy
3 episodes with Targeted therapy
5 episodes with Targeted therapy
4 episodes with Targeted therapy
12 episodes with Targeted therapy
2 episodes with Targeted therapy
3 episodes with Targeted therapy
3 episodes with Targeted therapy
4 episodes with Targeted therapy
5 episodes with Targeted therapy
3 episodes with Targeted therapy
4 episodes with Targeted therapy
Neurosurgeon Christina Jackson, MD, and radiation-oncologist Emily Lebow, MD, discuss the treatment of meningiomas, tumors of the meninges renowned for their tendency to recur following resection, andreview the tools used to image (DOTATATE-PET), target (Lutathera), and destroy (GammaTile) residual meningioma cells to prevent recurrence of the disease.
In this podcast, experts Manmeet Ahluwalia, MD, MBA; and Ashley S. Margol, MD, MS; discuss targeted therapies for adult and pediatric low-grade gliomas, pediatric diffuse midline glioma, and adult glioblastoma.
In this Part 1 of 2 ASCO 2026 Highlights episodes, hosts Dr. Narjust Florez and Dr. Stephen Liu are joined by Dr. Alice Shaw and Dr. Jonathan Goldman to review some of the most impactful targeted therapy data presented at the 2026 ASCO Annual Meeting. The discussion explores the practice-changing LIBRETTO-432 trial in early-stage RET-positive NSCLC, long-term outcomes with lorlatinib in ALK-positive disease, emerging data for neladalkib, and promising results for sunvozertinib in EGFR exon 20 insertion–positive NSCLC, highlighting how these findings may influence treatment decisions across disease stages. Guests: Dr. Alice Shaw. is a Professor of Medicine at Harvard Medical School, Chair of Medical Oncology, and a thoracic oncologist at Dana Farber Cancer Institute. She is widely recognized as a pioneer in the field of ALK-positive non-small cell lung cancer, having led landmark clinical trials that established crizotinib, ceritinib, and lorlatinib as standards of care. Dr. Jonathan W. Goldman is a Professor of Medicine and thoracic oncologist at the UCLA David Geffen School of Medicine, where he serves as a principal investigator in the Phase I drug development program. Dr. Goldman has been at the forefront of early-phase oncology trials across multiple tumor types, with a particular focus on novel therapeutics in lung cancer, and he was the presenting author of Libretto 432 at the plenary session at the 2026 ASCO
As part of the 2026 UCSF Patient Conference on Prostate Cancer, Dr. Jonathan Chou discusses targeted therapies. Series: "Prostate Cancer Patient Conference" [Health and Medicine] [Show ID: 41563]
As part of the 2026 UCSF Patient Conference on Prostate Cancer, Dr. Jonathan Chou discusses targeted therapies. Series: "Prostate Cancer Patient Conference" [Health and Medicine] [Show ID: 41563]
As part of the 2026 UCSF Patient Conference on Prostate Cancer, Dr. Jonathan Chou discusses targeted therapies. Series: "Prostate Cancer Patient Conference" [Health and Medicine] [Show ID: 41563]
Only one in three eligible lung cancer patients receives the targeted therapy they should get.That is not a failure of science.It is a failure of delivery.After more than two decades of precision oncology, biopharma has never had better tools: cell and gene therapy, in vivo CAR-T, antibody-drug conjugates, AI-enabled diagnostics, organoids, multi-omics, and global clinical data.Yet too many breakthroughs still fail to reach the bedside.Patients fall through fragmented systems.Data does not move cleanly.Community oncologists are overloaded.Tests are missed, delayed, or misread.Promising assets die in quarterly portfolio reviews.And healthcare systems built for pills, tablets, and chronic disease management are now being asked to deliver personalized medicine at scale.In this SPARK20 highlight episode, Alasdair Milton, PhD, Principal at KPMG and leader of the firm's Precision & Advanced Therapies practice, explains why the future of biopharma will not be decided by science alone.It will be decided by translation.From lab bench to boardroom.From data to decisions.From treatment to prevention.Alasdair brings more than 20 years of experience across life sciences strategy, commercial due diligence, precision medicine, advanced therapies, cell and gene therapy, biopharma M&A, diagnostics, and global healthcare transformation.This conversation moves from the precision medicine delivery crisis to China's biotech acceleration, from AI and organoids to trapped pharma assets, from lifelong wellness to the one skill every future biotech leader needs:The ability to translate complex science into business strategy, capital allocation, and patient impact.What You'll Learn in 22 MinutesWhy only one third of eligible lung cancer patients receive targeted therapy(00:01:53)And why precision medicine still breaks in everyday clinical practice.Why science keeps compounding even when systems fail(00:04:33)Including in vivo CAR-T, functional cures, gene therapy, and antibody-drug conjugates.Why innovation does not move in a straight line(00:05:20)How technologies can look dead for years before suddenly changing the market.Why China's biotech speed matters(00:07:36)How AI, organoids, scale, and execution are changing the global innovation map.Why great science dies inside Big Pharma(00:09:20)And how deprioritized assets can become billion-dollar companies when externalized properly.Why the industry must move from sickness to lifelong wellness(00:10:03)Alasdair's vision for a more proactive, preventive, data-driven healthcare system.Why pharma needs better ways to rescue shelved assets(00:13:06)Including examples such as SpringWorks, Cerevel, and new models for unlocking trapped value.How a 400-person Scottish island shaped Alasdair's worldview(00:15:07)The personal story behind his resilience, discipline, and leadership style.Why careers and companies are never linear(00:17:19)What Alasdair learned after moving to Boston and losing his role within weeks.Why the future belongs to translators(00:20:06)The most valuable skill in biotech: explaining complex science to business leaders, investors, and boards.How to connect with Alasdair Milton and the KPMG Precision & Advanced Therapies team(00:21:47)Quotes to Carry With You
Drs. Mantia and Berg continue their discussion of ESMO 2025 data on HER2‑directed antibody–drug conjugates in urothelial cancer and the importance of routine HER2 testing. They highlight the promising efficacy and manageable toxicity of these agents across disease stages and raise future questions about how best to sequence them.
Featuring proceedings from a live event on January 9, 2026, held adjunct to the 2026 ASCO Gastrointestinal Cancers Symposium and moderated by Dr Samuel J Klempner, including the following topics: Treatment approach for metastatic HER2-negative, claudin 18.2-positive, microsatellite instability-high gastroesophageal (GE) cancer (0:00) Duration of chemotherapy for patients with advanced GE cancers receiving nivolumab/chemotherapy (3:06) Younger patient with metastatic PD-L1-positive gastric cancer (5:29) CME information and select publications
Pediatric thyroid nodules are rare, but their risk of malignancy is significantly higher than in adults, raising the stakes for accurate diagnosis and multidisciplinary management. In this episode of the BackTable ENT Podcast Dr. Gopi Shah and co-host Dr. Jeff Hyzer interview Dr. Wen Jiang, pediatric otolaryngologist at Rady Children's Hospital in San Diego, for an in-depth discussion on the evaluation and management of thyroid nodules in children. --- Get the BackTable apphttps://www.backtable.com/app --- Timestamps 00:00 - Introduction 02:27 - Thyroid Nodule Risks and Care Team 06:47 - Age-related Differences in Nodule Presentation and Outcomes08:50 - Initial workup 13:42 - Ultrasound Interpretation16:07 - Lymph Node Mapping and CT19:58 - Incidental Findings24:14 - Role of FNA, Molecular Testing, and Radiofrequency Ablation32:40 - Molecular Testing Results and Counseling 38:04 - Neck Dissection Strategy40:44 - Hypocalcemia Protocol Considerations44:01 - Parathyroid and Recurrent Laryngeal Nerve Dissection Tips 47:33 - Postop Care and Follow-up 51:25 - Using Radioactive Iodine and Targeted Therapy 54:55 - AI's and Ultrasound and Final Thoughts --- More about this episode Dr. Jiang highlights the key differences between pediatric and adult thyroid nodules. She describes her multidisciplinary approach including collaboration with radiology, pathology, endocrinology and nuclear medicine. The discussion reviews the initial workup for pediatric thyroid nodules and why ultrasound remains the primary diagnostic tool. She also discusses situations where CT with contrast can be helpful for surgical planning. This episode explores the growing role of reflex molecular testing in guiding management decisions and outlines the impacts of molecular testing results. Dr. Jiang shares her approach to patient counseling along with management of calcium and PTH after surgery. The conversation concludes with emerging applications of molecular diagnostics and AI models for improving thyroid ultrasound interpretation. --- Resources Dr. Jiang's Research on Pediatric Thyroid Nodule Management - https://pubmed.ncbi.nlm.nih.gov/26770219/ Bethesda System for Thyroid Cytopathology - https://pmc.ncbi.nlm.nih.gov/articles/PMC7182964/ --- BackTable ENT & Allergy is the go-to podcast for otolaryngologists, allergists, and head and neck surgeons. Download the free BackTable app to get early access to new episodes, cases, and courses curated by physicians in your specialty. ► https://www.backtable.com/app
We're going to cure cancer in our lifetime." It's a rallying cry at every charity event, every fundraiser, every race. But what does that actually mean?Dr. Sonal Gandhi, a medical oncologist, joins Ditch the Labcoat to break down what most people don't understand: we already cure cancer. All the time. Early stage cancers like breast, colon, and skin cancer caught in time have cure rates approaching 90 to 100 percent.The challenge is stage four cancer. Metastatic disease. Cancer that has spread to other organs. And even there, the conversation is shifting. Cancer is increasingly becoming a chronic illness. People are living longer with it, sometimes dying with it rather than from it, just like they do with heart disease or diabetes.Dr. Gandhi walks through what "curing cancer" really means, how treatment has evolved beyond chemotherapy into targeted therapies and immunotherapy, and why prevention matters. Up to 40 percent of cancers are related to modifiable lifestyle factors: smoking, alcohol, obesity, lack of exercise. But even doing everything right doesn't guarantee you won't get cancer. Age is the number one risk factor, and we can't modify that.She also challenges the guilt people carry when they're diagnosed and reframes the fear around the "C word." Maybe it's time to pull cancer back into the middle with the menu of other chronic illnesses we manage, not cure.If you've ever wondered what "curing cancer" actually means, why some cancers are more treatable than others, or what you can do to reduce your risk, this episode will reframe how you think about one of medicine's most feared diagnoses.If you've ever wondered why so many people have unexplained symptoms, why standard treatments fail them, or what actually works when medicine runs out of answers, this episode will reframe how you see chronic illness.Dr. Sonal Gandhi's LinkedinEpisode Takeaways1. We already cure cancer. Early stage cancers (stage 1 or 2) caught in time have cure rates approaching 90 to 100 percent, depending on the type.2. Cancer is not one disease. It's dozens of diseases with different stages, treatments, and outcomes. We're better at treating some than others.3. Stage four (metastatic) cancer is increasingly becoming a chronic illness. Treatments help people live longer with cancer, sometimes dying with it rather than from it.4. Up to 40 percent of cancers are related to modifiable lifestyle factors: smoking, alcohol, obesity, and lack of exercise. Being a healthy weight matters for cancer prevention.5. Age is the number one risk factor for cancer. Every decade you get older, cells get worse at repairing mistakes. We can't modify aging.6. Only 10 to 20 percent of cancers are due to inherited genes. Most cancers happen because of the complicated interplay between lifestyle, environment, and cellular aging.7. Immunotherapy works by preventing cancer cells from turning off the immune system, but it can cause severe autoimmune side effects that need rapid treatment.8. Whole body scans and experimental blood tests sound appealing, but they often create more harm than good. Screening needs to be done in context with clear downstream action plans.Episode Timestamps03:51 – What Does "Curing Cancer" Actually Mean?08:15 – Early Stage vs. Late Stage Cancer: The Critical Difference12:42 – How Chemotherapy, Targeted Therapy, and Immunotherapy Work18:35 – Prevention: Lifestyle Factors That Reduce Cancer Risk21:50 – Why Immunotherapy Can Cause Severe Side Effects30:48 – Cancer as a Chronic Illness, Not a Death Sentence38:22 – Environmental and Occupational Cancer Risks45:51 – Why Whole Body Scans Aren't the AnswerDISCLAMER >>>>>> The Ditch Lab Coat podcast serves solely for general informational purposes and does not serve as a substitute for professional medical services such as medicine or nursing. It does not establish a doctor/patient relationship, and the use of information from the podcast or linked materials is at the user's own risk. The content does not aim to replace professional medical advice, diagnosis, or treatment, and users should promptly seek guidance from healthcare professionals for any medical conditions. >>>>>> The expressed opinions belong solely to the hosts and guests, and they do not necessarily reflect the views or opinions of the Hospitals, Clinics, Universities, or any other organization associated with the host or guests. Disclosures: Ditch The Lab Coat podcast is produced by (soundsdebatable.com) and is independent of Dr. Bonta's teaching and research roles at McMaster University, Temerty Faculty of Medicine and Queens University.
Good morning from Pharma Daily: the podcast that brings you the most important developments in the pharmaceutical and biotech world. The industry is buzzing with significant shifts driven by scientific advancements, strategic acquisitions, and regulatory changes. A noteworthy transaction is Bayer's $2.4 billion acquisition of Perfuse, aimed at gaining control over an eye disease implant that has shown promising results in phase 2 trials. This acquisition speaks to Bayer's commitment to expanding its ophthalmology portfolio, a field with substantial unmet medical needs due to aging populations. The move highlights how companies are investing heavily in areas expected to see growing patient demand. In the realm of artificial intelligence, Recursion Pharmaceuticals is undergoing a strategic transformation under new leadership. After a decade of AI-driven research without yielding tangible products, the focus is shifting towards translating AI's potential into viable therapeutic solutions. This reflects a broader industry trend where the promise of AI must be balanced with pragmatic strategies to ensure commercial success. Novo Nordisk is making strides with its GLP-1/amylin combo treatment Cagrisema, maintaining its launch plans despite technical setbacks with a single-chamber device design. This demonstrates the company's adaptability in overcoming hurdles to bring innovative diabetes treatments to market, crucial in the competitive landscape of diabetes care. Additionally, Novo Nordisk's obesity treatment Wegovy has posted impressive quarterly revenues of $355 million thanks to strategic pricing and timely market entry ahead of competitors like Eli Lilly in the emerging oral obesity therapy segment. Such success suggests potential redefinition of market dynamics in obesity treatments. GlaxoSmithKline has entered into a $1 billion agreement with China's Siranbio for an oligonucleotide therapy targeting abdominal fat reduction. This partnership highlights GSK's strategic focus on cardiometabolic diseases through nucleic acid-based therapies, which offer high specificity and efficacy. Such therapeutics are becoming increasingly attractive for investment due to their potential impact on diverse health conditions. CellCentric's successful Series D funding round, raising $220 million for its myeloma drug, positions it well for pursuing clinical milestones independently. This signifies a shift towards self-reliant biotech models, illustrating how smaller companies are increasingly able to navigate the drug development landscape without traditional pharma partnerships. Gilead's acquisition of Arcellx for $7.8 billion and its subsequent workforce consolidation reflect ongoing realignments within the CAR-T therapy space. These consolidations indicate strategic prioritization within large biopharmaceutical companies to streamline operations while focusing on promising therapeutic areas like CAR-T cells. In corporate restructuring news, Gilead Sciences announced workforce reductions following its acquisition of Arcellx. While aimed at optimizing operations post-acquisition, it raises concerns about job security amid increasing merger activities within the biotech sector. Avalo's promising phase 2 results in skin disease treatment have renewed interest despite challenges from placebo comparisons. This emphasizes the competitive dynamics and high stakes in dermatological drug development, where even modest efficacy signals can significantly drive market activity. BioCryst's decision to halt its diabetic macular edema program to concentrate on rare diseases exemplifies a strategic pivot towards niche markets with potentially higher returns and less competition. This aligns with broader industry trends emphasizing precision medicine and targeted therapies. Eli Lilly's substantial $4.5 billion investment into its Indiana manufacturing complex underscores a commiSupport the show
BUFFALO, NY – May 6, 2026 – A new #casereport was #published in Volume 17 of Oncotarget on May 4, 2026, titled “Small bowel GIST harboring concurrent KIT exon 9 duplication and SDHC mutation: A case report.” The study was led by first author Cameron B. Speyer from the UCLA David Geffen School of Medicine, and corresponding author Joseph G. Crompton, who holds appointments at both the UCLA David Geffen School of Medicine and the Jonsson Comprehensive Cancer Center. In this report, the authors describe a rare and clinically informative case of a small bowel gastrointestinal stromal tumor (GIST) harboring two genetic alterations that are typically considered mutually exclusive. GISTs are most commonly driven by activating mutations in the KIT or PDGFRA genes, which confer sensitivity to targeted therapies such as imatinib. In contrast, tumors associated with succinate dehydrogenase (SDH) deficiency represent a distinct subgroup that is generally resistant to these treatments. The patient, a 68-year-old man, presented with progressive abdominal pain, bloating, and constipation. Imaging studies revealed a large heterogeneous mass in the lower abdomen measuring up to 18 cm. A biopsy confirmed a spindle cell neoplasm consistent with GIST, with immunohistochemical staining positive for CD117 and DOG1. Genomic analysis identified both a KIT exon 9 duplication (A502_Y503) and a germline SDHC mutation (p.R50C)—a highly unusual combination. Despite the presence of the SDHC mutation, which is typically associated with resistance to therapy, the patient demonstrated a strong response to high-dose imatinib. After six months of neoadjuvant treatment, imaging showed a marked reduction in tumor size and metabolic activity, enabling successful surgical resection. “This case suggests that oncogenic KIT signaling may remain the dominant driver of GIST behavior despite the presence of a germline SDHC mutation and highlights the importance of integrated molecular interpretation in GIST management.” Pathologic examination of the resected tumor revealed significant treatment response, including extensive necrosis and reduced tumor viability. Notably, immunohistochemistry demonstrated retained SDHB expression, indicating preserved SDH complex function despite the identified germline mutation. The case highlights an important clinical insight: not all detected genetic alterations contribute equally to tumor behavior. While SDH-deficient GISTs are typically resistant to imatinib, this tumor behaved in a manner consistent with KIT-driven disease, underscoring the importance of interpreting molecular findings within their clinical and pathological context. Overall, this report emphasizes the need for integrated molecular analysis in cancer diagnosis and treatment. As next-generation sequencing becomes more widely used, clinicians may encounter tumors with multiple coexisting mutations. Determining the dominant oncogenic driver is essential for selecting the most effective therapy and improving patient outcomes. DOI - https://doi.org/10.18632/oncotarget.28863 Correspondence to - Joseph G. Crompton - jcrompton@mednet.ucla.edu Abstract video - https://www.youtube.com/watch?v=eB_QG2vBNCE Subscribe for free publication alerts from Oncotarget - https://www.oncotarget.com/subscribe/ Keywords - cancer, GIST, KIT duplication, SDHC mutation, genetic testing, case report To learn more about Oncotarget, please visit https://www.oncotarget.com and connect with us: Facebook - https://www.facebook.com/Oncotarget/ X - https://twitter.com/oncotarget Instagram - https://www.instagram.com/oncotargetjrnl/ YouTube - https://www.youtube.com/@OncotargetJournal LinkedIn - https://www.linkedin.com/company/oncotarget Pinterest - https://www.pinterest.com/oncotarget/ Reddit - https://www.reddit.com/user/Oncotarget/ Spotify - https://open.spotify.com/show/0gRwT6BqYWJzxzmjPJwtVh MEDIA@IMPACTJOURNALS.COM
BUFFALO, NY – April 29, 2026 – A new #research paper was #published in Volume 17 of Oncotarget on April 28, 2026, titled “Targeted therapeutics and U.S. population-level mortality trends in multiple myeloma: A SEER-based analysis from 1975 to 2023.” The study was led by first and corresponding author Navkirat Kahlon from the Mass General Cancer Center at Wentworth-Douglass Hospital, in collaboration with researchers from multiple U.S. institutions. In this study, the researchers examined how mortality trends in multiple myeloma have changed in the United States over nearly five decades, using population-level data from the SEER database. Multiple myeloma, a cancer of plasma cells, has historically been associated with poor survival outcomes, but treatment options have evolved dramatically over time. The analysis revealed a clear shift in mortality trends that closely parallels major therapeutic advances. Between 1975 and the mid-1990s, mortality rates steadily increased, reflecting the limited effectiveness of early treatments such as alkylating agents and corticosteroids. A turning point emerged in the 1990s with the introduction of autologous stem cell transplantation, which marked the first meaningful improvement in survival outcomes. Over the following years, the development of targeted therapies—including immunomodulatory drugs and proteasome inhibitors—was associated with a more pronounced decline in mortality. These treatments introduced new mechanisms of action, such as immune modulation and enhanced cancer cell apoptosis, significantly improving disease control. More recent years have seen further progress with the introduction of monoclonal antibodies, maintenance therapies, and combination treatment strategies. Notably, the steepest decline in mortality occurred between 2021 and 2023, coinciding with the clinical adoption of advanced immunotherapies such as CAR T-cell therapies and bispecific antibodies. These treatments have shown the ability to induce deep and durable responses, even in heavily pretreated patients. “Our findings highlight the real-world impact of targeted therapies on population-level outcomes and underscore the urgent need for care models that ensure accessibility, affordability, and long-term sustainability in the era of precision oncology.” Importantly, while these therapeutic advances have improved survival, they have also introduced new challenges. Many patients now require long-term treatment, which can be associated with cumulative toxicities and a significant financial burden. In addition, access to these therapies remains uneven, influenced by geographic, socioeconomic, and healthcare system factors. Overall, this study provides a comprehensive, real-world view of how advances in cancer treatment have translated into measurable improvements in survival at the population level. At the same time, it highlights the need to ensure that these benefits are both sustainable and accessible to all patients as the field continues to evolve. DOI - https://doi.org/10.18632/oncotarget.28877 Correspondence to - Navkirat Kahlon - nkahlon@mgb.org; (ORCID: https://orcid.org/0000-0003-1115-2029) Abstract video - https://www.youtube.com/watch?v=-TNWkG9FyUo Subscribe for free publication alerts from Oncotarget - https://www.oncotarget.com/subscribe/ To learn more about Oncotarget, please visit https://www.oncotarget.com and connect with us on social media: Facebook - https://www.facebook.com/Oncotarget/ X - https://twitter.com/oncotarget Instagram - https://www.instagram.com/oncotargetjrnl/ YouTube - https://www.youtube.com/@OncotargetJournal LinkedIn - https://www.linkedin.com/company/oncotarget Pinterest - https://www.pinterest.com/oncotarget/ Reddit - https://www.reddit.com/user/Oncotarget/ Spotify - https://open.spotify.com/show/0gRwT6BqYWJzxzmjPJwtVh MEDIA@IMPACTJOURNALS.COM
ReferencesSignal Transduction and Targeted Therapy 2025. 10.216. J Neuroinflammation. 2019; 16: 236. Guerra, DJ. 2026. Unpublished LecturesMozart, WA. 1791. Clarinet Concerto in A Major K.622https://music.youtube.com/watch?v=YT_63UntRJE&si=WdJgqsHUf36yHd_MWelch/McVie/McVie and Kirwan. 1971. Woman of a 1000 years. Fleetwood Mac https://open.spotify.com/track/6aE623nY6WVhgYH9VAFQRr?si=05d6b9bffb3941a6Paige. 1970. Tangerine. Led Zeppelinhttps://open.spotify.com/track/4ywWJqYKOwaVVh9xXARWUS?si=00c587e7946f4179
Featuring perspectives from Dr Jaffer A Ajani, Dr Samuel J Klempner, Dr Rutika Mehta and Dr John Strickler, moderated by Dr Klempner, including the following topics: Role of PD-L1 status, tumor histology and pulmonary disease in selection of immune checkpoint inhibition as up-front therapy (0:00) Impact of metastatic site and autoimmune disease on clinical decision-making in the use of immune checkpoint inhibition (5:56) Biomarker assessment approach and treatment selection (10:50) CME information and select publications
Dr Jaffer Ajani from The University of Texas MD Anderson Cancer Center in Houston, Dr Samuel Klempner from Massachusetts General Hospital in Boston, Dr Rutika Mehta from Weill Cornell Medicine/NewYork-Presbyterian Hospital in New York, New York, and Dr John Strickler from Duke University in Durham, North Carolina, review relevant data supporting immunotherapy for patients with gastroesophageal cancers and review recently presented clinical findings from the 2026 ASCO Gastrointestinal Cancers Symposium. CME information and select publications here.
SHOW NOTES:On this episode host Jonathan Chance talks with guest, Dr. Perter Rossi about Whole Gland vs. Targeted Therapy for prostate cancer. Jonathan and Dr. Rossi discuss: · The difference between treating the whole prostate and just targeting the tumor.· What men should they know about, when choosing a prostate cancer treatment option.· Active surveillance as opposed to immediate treatment for prostate cancer.· How we're moving toward a future - where more men can avoid aggressive treatments· What is focal therapy and brachytherapy for treating prostate cancer Prostate Cancer Aware is grateful to the Jevan and Ruzanna Chimayan Foundation for their generous donation, which helps fuel our podcast and website to raise critical awareness about prostate cancer and the PSA test around the world.Prostate Cancer Aware is a copyrighted production. No content maybe rebroadcast or reproduced without the expressed written consent of the Friedman Sidrow Foundation. For more information about prostate cancer, the PSA test, men's health and Jonathan's inspiring new book Unaware, which is about his battle with prostate cancer.Visit our website at: https://www.iknowmypsa.orgEmail us at: https://www.iknowmypsa.org/contactus/Follow Prostate Cancer Aware on social media at:Facebook - https://www.facebook.com/iknowmypsa Twitter - https://twitter.com/iknowmypsa or @iknowmypsaThank you for listening! Remember, Stay Aware and Stay Healthy.™
This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/NCPD/AAPA information, and to apply for credit, please visit us at PeerView.com/WFA865. CME/NCPD/AAPA credit will be available until April 16, 2027.Adapting to Innovation in B-Cell Cancers: Advances With Targeted Therapy & CAR-T and Revisiting the Role of Transplant In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported through independent educational grants from AstraZeneca and Bristol Myers Squibb.Disclosure information is available at the beginning of the video presentation.
This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/NCPD/AAPA information, and to apply for credit, please visit us at PeerView.com/WFA865. CME/NCPD/AAPA credit will be available until April 16, 2027.Adapting to Innovation in B-Cell Cancers: Advances With Targeted Therapy & CAR-T and Revisiting the Role of Transplant In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported through independent educational grants from AstraZeneca and Bristol Myers Squibb.Disclosure information is available at the beginning of the video presentation.
This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/NCPD/AAPA information, and to apply for credit, please visit us at PeerView.com/WFA865. CME/NCPD/AAPA credit will be available until April 16, 2027.Adapting to Innovation in B-Cell Cancers: Advances With Targeted Therapy & CAR-T and Revisiting the Role of Transplant In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported through independent educational grants from AstraZeneca and Bristol Myers Squibb.Disclosure information is available at the beginning of the video presentation.
This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/NCPD/AAPA information, and to apply for credit, please visit us at PeerView.com/WFA865. CME/NCPD/AAPA credit will be available until April 16, 2027.Adapting to Innovation in B-Cell Cancers: Advances With Targeted Therapy & CAR-T and Revisiting the Role of Transplant In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported through independent educational grants from AstraZeneca and Bristol Myers Squibb.Disclosure information is available at the beginning of the video presentation.
This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/NCPD/AAPA information, and to apply for credit, please visit us at PeerView.com/WFA865. CME/NCPD/AAPA credit will be available until April 16, 2027.Adapting to Innovation in B-Cell Cancers: Advances With Targeted Therapy & CAR-T and Revisiting the Role of Transplant In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported through independent educational grants from AstraZeneca and Bristol Myers Squibb.Disclosure information is available at the beginning of the video presentation.
This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/NCPD/AAPA information, and to apply for credit, please visit us at PeerView.com/WFA865. CME/NCPD/AAPA credit will be available until April 16, 2027.Adapting to Innovation in B-Cell Cancers: Advances With Targeted Therapy & CAR-T and Revisiting the Role of Transplant In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported through independent educational grants from AstraZeneca and Bristol Myers Squibb.Disclosure information is available at the beginning of the video presentation.
Dr. Robert Rifkin, medical oncologist and hematologist at the University of Colorado in Steamboat Springs. He was also a clinical investigator in the trial that led to the approval of BLENREP, a multiple myeloma drug from GSK. Multiple myeloma is the second most common blood cancer, and while the prognosis has dramatically improved, BLENREP is a novel treatment for patients whose disease has relapsed after other therapies. It is the first drug antibody conjugate approved for relapsed multiple myeloma, targeting the BCMA antigen, which is present on nearly all myeloma cells. Robert explains, "This is a condition that is really what I would call a disease of the Medicare population. So the median age of diagnosis is often early 60s, but occasionally you do see the younger patients with more aggressive disease. It's thought that African Americans who contract myeloma also may have a more virulent form of the disease." "Right now we live in a great day and age where we have a tremendous number of good treatments, both upfront, which we really won't be discussing today. And then in patients that have unfortunately relapsed and failed other lines of therapy, that's where the exciting new drug BLENREP comes into play. It's going to have a very specific slot in the myeloma armamentarium." "So BLENREP is unique in that it targets something on the myeloma cells called the BCMA target or B-cell maturation antigen target. That's expressed in 98% of patients with myeloma. So it provides a really great target to shoot at, if you will. Right now, we really have sort of three main classes of therapy to go after it: CAR T-cells and bispecific antibodies that your audience will likely be familiar with. This one is unique in that it's the first drug antibody conjugate approved to treat myeloma. So it's not a cellular therapy, but instead it's a molecule that has the BCMA that binds to the myeloma cells, and then it unloads a payload to kill the myeloma cells. So that's nice. You don't have to go to a huge center with experience in cellular therapies. It can be done readily in the community." #MultipleMyeloma #Oncology #BLENREP #BloodCancer #Belamaf #CancerResearch #Hematology #ClinicalTrials #PrecisionMedicine #CancerTreatment #MedicalAdvancement blenrephcp.com Listen to the podcast here
Dr. Robert Rifkin, medical oncologist and hematologist at the University of Colorado in Steamboat Springs. He was also a clinical investigator in the trial that led to the approval of BLENREP, a multiple myeloma drug from GSK. Multiple myeloma is the second most common blood cancer, and while the prognosis has dramatically improved, BLENREP is a novel treatment for patients whose disease has relapsed after other therapies. It is the first drug antibody conjugate approved for relapsed multiple myeloma, targeting the BCMA antigen, which is present on nearly all myeloma cells. Robert explains, "This is a condition that is really what I would call a disease of the Medicare population. So the median age of diagnosis is often early 60s, but occasionally you do see the younger patients with more aggressive disease. It's thought that African Americans who contract myeloma also may have a more virulent form of the disease." "Right now we live in a great day and age where we have a tremendous number of good treatments, both upfront, which we really won't be discussing today. And then in patients that have unfortunately relapsed and failed other lines of therapy, that's where the exciting new drug BLENREP comes into play. It's going to have a very specific slot in the myeloma armamentarium." "So BLENREP is unique in that it targets something on the myeloma cells called the BCMA target or B-cell maturation antigen target. That's expressed in 98% of patients with myeloma. So it provides a really great target to shoot at, if you will. Right now, we really have sort of three main classes of therapy to go after it: CAR T-cells and bispecific antibodies that your audience will likely be familiar with. This one is unique in that it's the first drug antibody conjugate approved to treat myeloma. So it's not a cellular therapy, but instead it's a molecule that has the BCMA that binds to the myeloma cells, and then it unloads a payload to kill the myeloma cells. So that's nice. You don't have to go to a huge center with experience in cellular therapies. It can be done readily in the community." #MultipleMyeloma #Oncology #BLENREP #BloodCancer #Belamaf #CancerResearch #Hematology #ClinicalTrials #PrecisionMedicine #CancerTreatment #MedicalAdvancement blenrephcp.com Download the transcript here
Stop applying to medical sales jobs online. You're doing it wrong.In this episode of Medical Sales U, I sit down with Todd Ford, National Sales Director at Guardant Health, to pull back the curtain on what it actually takes to lead and land a role in the high-stakes world of precision medicine and oncology diagnostics.Todd has hired over 150+ people at Guardant alone, and his data is clear: only 1 in 65 successful hires comes from an online application. So, how do you get in? We break down the "networking secret," the evolution of genomic testing (NGS), and the daily habits of the top 10% of sales reps who win President's Club year after year.In this episode, you'll learn:Why B2B sales (like copiers) is the ultimate stepping stone to Medical Sales.The "hidden" criteria Todd uses to hire D1 athletes and top-tier talent.How Precision Medicine shifted from Chemotherapy to Targeted Therapy.The reality of "The Hustle": Managing 160 flights a year while raising a family.Why your resume is the least important part of your job search.TIMESTAMPS:0:00 - Introduction: Meet Todd Ford of Guardant Health2:15 - The 10-Year Evolution: From Chemo to Precision Medicine4:40 - Career Roots: Why a Mentor told Todd to sell Copiers first7:00 - Scaling the MRD (Minimal Residual Disease) Team9:30 - How to Move from Sales Rep to National Director12:15 - The "Ante" to get to the table: Consistent Performance15:00 - Hiring Secrets: The "1 in 65" Networking Rule18:30 - Managing the Autonomy: Habits of a Remote Sales Leader21:00 - The Travel Reality: 160 Flights vs. Family Life24:00 - The President's Club: Ritz-Carlton Yachts & Rewards28:00 - Final Advice: Why Initiative is your best Interview ToolCONNECT WITH THE GUEST:Todd Ford on LinkedIn: https://www.linkedin.com/in/todd-ford-914b34/Guardant Health: https://guardanthealth.com/ABOUT MEDICAL SALES U:We help aspiring and veteran sales professionals break into and level up within the medical device, pharmaceutical, and diagnostic industries. Subscribe for weekly interviews with the leaders shaping the future of medicine. We help professionals transition into top-tier medical sales roles: medicalsalesu.com/#MedicalSales #PrecisionMedicine #Oncology #GuardantHealth #SalesLeadership #MedicalDeviceSales #JobSearchTips #PresidentClub #SalesHabits
Featuring perspectives from Dr Jaffer A Ajani, Dr Samuel J Klempner, Dr Rutika Mehta and Dr John Strickler, moderated by Dr Klempner, including the following topics: Older patient with metastatic claudin 18.2-positive gastroesophageal (GE) cancer (0:00) Management of nausea and vomiting with zolbetuximab for GE cancer (9:37) Younger patient with metastatic claudin 18.2-positive, PD-L1-positive GE cancer (15:34) CME information and select publications
In this podcast, experts Patrick I. Borgen, MD; Don S. Dizon, MD, FACP, FASCO; Kevin S. Hughes, MD, FACS; and Banu Arun, MD, FASCO; discuss how genetic testing drives breast cancer management from screening and surgical decisions to targeted systemic therapies.
Dr Jaffer Ajani from The University of Texas MD Anderson Cancer Center in Houston, Dr Samuel Klempner from Massachusetts General Hospital in Boston, Dr Rutika Mehta from Weill Cornell Medicine/NewYork-Presbyterian Hospital in New York, New York, and Dr John Strickler from Duke University in Durham, North Carolina, review relevant data supporting immunotherapy for patients with gastroesophageal cancers and recently presented clinical findings from the 2026 ASCO Gastrointestinal Cancers Symposium.CME information and select publications here.
HER2-Positive Biliary Tract Cancer: Biomarkers, Targeted Therapy, and Managed Care Access On this episode, Jeffrey Dunn, PharmD, MBA, President and CEO of Cooperative Benefits Group, discusses the rapidly evolving treatment landscape for HER2-positive biliary tract cancer (BTC) and its implications for managed care. The discussion covers the importance of biomarker testing and molecular profiling in guiding targeted therapy, key NCCN guideline considerations across lines of treatment, and the clinical and economic impact of timely access to HER2-directed therapies. We also discuss payer-provider collaboration strategies to improve testing, coverage alignment, and patient access in this rare and aggressive form of cancer. Find all of our network podcasts on your favorite podcast platforms and be sure to subscribe and like us. Learn more at www.healthcarenowradio.com/listen/
Featuring perspectives from Dr Jaffer A Ajani, Dr Samuel J Klempner, Dr Rutika Mehta and Dr John Strickler, moderated by Dr Klempner, including the following topics: Younger patient with metastatic HER2-positive, PD-L1-positive gastric cancer (0:00) Older patient with metastatic HER2-positive gastroesophageal (GE) cancer (8:13) Clinical applications for zanidatamab in GE cancer (13:58) CME information and select publications
Dr Jaffer Ajani from The University of Texas MD Anderson Cancer Center in Houston, Dr Rutika Mehta from Weill Cornell Medicine/NewYork-Presbyterian Hospital in New York, New York, Dr John Strickler from Duke University in Durham, North Carolina, and moderator Dr Samuel Klempner from Massachusetts General Hospital in Boston review relevant data supporting immunotherapy for patients with gastroesophageal cancers and review recently presented clinical findings from the 2026 ASCO Gastrointestinal Cancers Symposium.CME information and select publications here.
Dr Jaffer Ajani from The University of Texas MD Anderson Cancer Center in Houston, Dr Rutika Mehta from Weill Cornell Medicine/NewYork-Presbyterian Hospital in New York, New York, Dr John Strickler from Duke University in Durham, North Carolina, and moderator Dr Samuel Klempner from Massachusetts General Hospital in Boston review relevant data supporting immunotherapy for patients with gastroesophageal cancers and review recently presented clinical findings from the 2026 ASCO Gastrointestinal Cancers Symposium.CME information and select publications here.
Undifferentiated Pleomorphic Sarcomas are one of the most common sarcomas. This class of tumors are aggressive with a risk of local recurrence and distant metastasis. We discuss the presentation, diagnostic challenges, and management of these sarcomas. Bennett C, Bharadwaj S, Arndt A, Chawla A. A systematic review of undifferentiated pleomorphic sarcoma of the chest wall. Chin Clin Oncol. 2023 Dec;12(6):66. Lesovaya EA, Fetisov TI, Bokhyan BY, Senchenko MA, Rogozhin DV, Maksimova VP, Demko AN, Belitsky GA, Yakubovskaya MG, Kirsanov KI. Genetic Heterogeneity of Undifferentiated Pleomorphic Sarcoma: Is There Potential for Targeted Therapy? Cancers (Basel). 2025 Nov 10;17(22):3613 Sun H, Liu J, Hu F, Xu M, Leng A, Jiang F, Chen K. Current research and management of undifferentiated pleomorphic sarcoma/myofibrosarcoma. Front Genet. 2023 Feb 16;14:1109491 xFind out More about our Doctors: Dr. Izuchukwu Ibe: www.linkedin.com/in/izuchukwu-ibe-a073537a/ Dr. Elyse Brinkmann: www.linkedin.com/in/elyse-brinkmann/
In this episode of Lung Cancer Considered, host Dr. Narjust Florez conducts three mock molecular tumor boards with Dr. Misako Nagasaka and Dr. Biagio Ricciuti, live from the Targeted Therapies of Lung Cancer (TTLC) 2026 conference. The discussion addresses the question, “How do we get the right molecular answer, at the right time, for the right patient?” Guests: Misako Nagasaka, MD, PhD Associate Clinical Professor University of California, Irvine Biagio Ricciuti, MD, PhD Thoracic Medical Oncologist, Dana-Farber Cancer Institute Faculty, Harvard School of Medicine
In this episode of Lung Cancer Considered, host Dr. Narjust Florez and guest Dr. Sam Rosner examine controversies around antibody-drug conjugates (ADCs) live from the 2026 Targeted Therapies of Lung Cancer (TTLC) conference. Guest: Sam Rosner, MD Assistant Professor of Medicine, University of Maryland School of Medicine Thoracic Medical Oncologist, University of Maryland Marlene and Stewart Greenebaum Comprehensive Cancer Center
In this episode, Dr Paz-Ares and Dr Christine Bestvina discuss the evolving role of KRAS G12C inhibitors in non-small-cell lung cancer (NSCLC), including: Clinical outcomes and limitations of first-generation KRAS G12C inhibitors Key unmet needs, including primary and acquired resistance Emerging strategies, including next-generation inhibitors and combination approaches with chemotherapy and immunotherapy Presenters: Luis Paz-Ares, MD, PhD Head of Medical Oncology Department Hospital Universitario 12 de Octubre Associate Professor, Universidad Complutense de Madrid Madrid, Spain Christine Bestvina, MD Associate Professor University of Chicago Medicine Division of Medicine Section of Hematology/Oncology University of Chicago Medicine Chicago, IllinoisLink to full program:https://bit.ly/4rhoUuN Get access to all of our new podcasts by subscribing to the Decera Clinical Education Oncology Podcast on Apple Podcasts, YouTube Music, or Spotify. Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.
In this episode of Lung Cancer Considered, host Dr. Narjust Florez explores controversies in managing lung cancer patients with comorbidities – those often underrepresented in clinical trials – with Dr. Hina Khan and Dr. Corey Langer, live from the Targeted Therapies of Lung Cancer (TTLC) 2026 conference. The discussion examines treatment decision-making in patients with ECOG performance status 2, renal dysfunction, advanced age, and complex comorbid conditions, emphasizing careful phenotyping, geriatric assessment, and individualized risk–benefit evaluation. The episode also highlights the balance between efficacy, toxicity, quality of life, and patient goals when treating the patients most commonly seen in clinical practice. Guests: Hina Khan, MD Thoracic Oncologist Assistant Professor of Medicine Warren Alpert Medical School, Brown University Corey Langer, MD, FACP Director, Thoracic Oncology, Abramson Cancer Center Professor of Medicine , Perelman School of Medicine University of Pennsylvania
Good morning from Pharma Daily: the podcast that brings you the most important developments in the pharmaceutical and biotech world. Today, we're diving into some pivotal advancements and strategic shifts within the industry, highlighting how these changes are shaping the future of patient care and drug development.Let's start with Bristol Myers Squibb, which has been making headlines with its latest success in the realm of antibody-drug conjugates (ADCs). The company's ADC has reached an important milestone in a Phase 3 breast cancer trial conducted in China. This study successfully met its dual primary survival endpoints, affirming the company's significant $800 million investment in this promising drug candidate. The potential of ADCs in oncology cannot be overstated; they offer a remarkable combination of targeted therapy by harnessing the specificity of antibodies alongside the cytotoxic power of traditional chemotherapy. This approach not only enhances precision in treatment but also minimizes collateral damage to healthy tissues, showcasing the transformative potential of ADCs in cancer therapy.On the regulatory front, there are ongoing discussions about the impact of political decisions on drug pricing and innovation. The Trump administration's Most Favored Nation drug pricing policy has stirred significant concern within the biotech sector. In response, ten midsize biotech firms have united to form the Midsized Biotech Alliance of America to challenge this policy. They argue that such pricing strategies could hinder innovation by enforcing restrictive pricing models, potentially stalling the development pipeline for new therapies that address unmet medical needs.In terms of strategic corporate movements, Boehringer Ingelheim has entered into a $500 million partnership with a British biotech firm aimed at developing an oral therapy for autoimmune diseases. This collaboration is part of a broader trend towards precision medicine which focuses on modulating specific immune cells to improve treatment outcomes while minimizing unwanted side effects. It's a clear indication that companies are increasingly investing in targeted therapies that promise better efficacy and patient safety. Additionally, Boehringer Ingelheim's partnership with Sitryx underscores another trend: strategic partnerships aimed at innovative research endeavors with substantial investment commitments—potentially exceeding $500 million—to explore immune response modulation.The acquisition landscape is also seeing dynamic shifts. Asahi Kasei's acquisition of Germany's AiCuris for $920 million marks a strategic move to enhance its R&D capabilities, specifically focusing on antiviral therapies for immunocompromised patients. This acquisition aligns with growing global attention towards infectious disease research, especially in a post-pandemic era where preparedness and rapid response capabilities have become paramount.Meanwhile, Sarepta Therapeutics is undergoing a significant leadership change as CEO Doug Ingram announces his retirement. Ingram's leadership was characterized by notable advancements in treatments for Duchenne muscular dystrophy (DMD), although it wasn't without its share of challenges regarding regulatory and pricing debates. As Sarepta continues to expand its gene therapy pipeline, this leadership transition comes at a crucial juncture, potentially setting new directions for the company's future.Accent Therapeutics' recent decision to halt its solid tumor trial due to adverse events exemplifies the risks inherent in drug development. The company is now redirecting its focus towards other cancer programs, illustrating how adaptability remains key in navigating clinical setbacks.Protagonist Therapeutics has made a strategic choice by accepting a $400 million payment from Takeda instead of sharing profits from its hematology asset rusfertide. This decision may provideSupport the show
Drs. Cytryn, Foote, and Thummalapalli discuss recent data on HER2 testing modalities and the prevalence of HER2 positivity across hepatobiliary, upper GI, and colorectal cancers, highlighting implications for precision medicine. The conversation reviews the latest clinical trial findings and the evolving landscape of HER2-targeted therapies, with insights into optimal treatment sequencing for various GI cancer subtypes.
Dr. Lakshmi Rajdev and Dr. Manish Shah join the podcast to discuss the updated guideline on immunotherapy and targeted therapy in unresectable locally advanced, advanced, or metastatic gastroesophageal cancer. They share first-line and subsequent-line recommendations for both gastroesophageal adenocarcinoma and esophageal squamous cell carcinoma based on actionable biomarkers including PD-L1 expression, MMR and/or MSI, CLDN18.2 expression, and HER2 status. They note the importance of the algorithms and tables in the guidelines that provide visual illustrations and quick reference guides of the evidence-based recommendations. They also comment on ongoing and recently presented trials that may impact future guidelines in this space. Read the full guideline, "Immunotherapy and Targeted Therapy for Advanced Gastroesophageal Cancer: ASCO Guideline Update" at www.asco.org/gastrointestinal-cancer-guidelines" TRANSCRIPT This guideline, clinical tools and resources are available at www.asco.org/gastrointestinal-cancer-guidelines. Read the full text of the guideline and review authors' disclosures of potential conflicts of interest in the Journal of Clinical Oncology, https://ascopubs.org/doi/10.1200/JCO-25-02958 Timestamps · 00:00 – 02:15 Introduction and Overview · 02:16 - 08:20 First-line treatment for patients with pMMR/MSS, HER2-negative gastroesophageal adenocarcinoma · 08:21 –10:29 First-line treatment for patients with pMMR/MSS, HER2-positive gastroesophageal adenocarcinoma · 10:30 – 14:39 First-line treatment for patients with dMMR/MSI-H, gastroesophageal adenocarcinoma · 14:40 – 18:03 First-line treatment for ESCC · 18:04 – 22:04 Second- and third-line therapy for gastroesophageal adenocarcinoma and ESCC · 22:05 – 24:38 Importance of guideline · 24:39 – 27:45 Outstanding questions and future research Brittany Harvey: Hello and welcome to the ASCO Guidelines podcast, one of ASCO's podcasts delivering timely information to keep you up to date on the latest changes, challenges, and advances in oncology. You can find all the shows, including this one, at asco.org/podcasts. My name is Brittany Harvey, and today I am interviewing Dr. Lakshmi Rajdev from the Icahn School of Medicine at Mount Sinai and Dr. Manish Shah from Weill Cornell Medicine, co-chairs on "Immunotherapy and Targeted Therapy for Advanced Gastroesophageal Cancer: ASCO Guideline Update." Thank you for being here today, Dr. Rajdev and Dr. Shah. Dr. Lakshmi Rajdev: Thank you. Dr. Manish Shah: Thank you for having us. It is wonderful. Brittany Harvey: And then just before we discuss this guideline, I would like to note that ASCO takes great care in the development of its guidelines and ensuring that the ASCO conflict of interest policy is followed for each guideline. The disclosures of potential conflicts of interest for the guideline panel, including Dr. Rajdev and Dr. Shah, who have joined us here today, are available online with the publication of the guideline in the Journal of Clinical Oncology, which is linked in the show notes. So then to dive into what we are here today to talk about, Dr. Shah, I would like to start first with what prompted the update to this guideline, which was previously published in 2023, and what is the scope of this updated guideline? Dr. Manish Shah: Yes, terrific. So even in the last few years, the pace of drug development in gastroesophageal cancers has just been astounding. So, what prompted this guideline is actually the practice-changing results for a new biomarker, CLDN18.2 hat was based on the GLOW and SPOTLIGHT studies, as well as a practice-changing study in HER2-positive disease where we added pembrolizumab to trastuzumab and chemotherapy for tumors that are HER2-positive and PD-L1 CPS 1 or greater. And then there were also new studies and new approvals in esophageal squamous cell cancer that you will hear about as well. So there were several studies, overall more than 5,000 patients were reported on, and that led to several new therapies, new indications, and it really necessitated this guideline. Brittany Harvey: Excellent. It is great to hear about all of these exciting updates in this space. So then to next review the key recommendations of this guideline by clinical question that the expert panel addressed. So, Dr. Rajdev, what is the recommended first-line treatment for patients with proficient mismatch repair, microsatellite stable, HER2-negative gastroesophageal adenocarcinoma? Dr. Lakshmi Rajdev: Thank you for that question. So historically, we have sort of used fluoropyrimidine and platinum doublets, which yielded a survival of about one year. More recently, immunotherapy and targeted therapy options have improved outcomes in patients with advanced esophageal and gastric adenocarcinoma, as well as squamous cell carcinoma. Patients with gastric and GE junction adenocarcinoma have a high rate of actionable alterations, so it is imperative that physicians test the following biomarkers upfront so that it can help guide therapy. The markers recommended by the ASCO panel are HER2, MMR or MSI, CLDN18.2, and PD-L1. And also, it was recommended to use NGS if feasible in this patient population. HER2, as we know, is expressed in about 15% to 25% of patients; PD-L1 expression occurs in about 80% of patients; MSI-high, deficient MMR is present in about 5% to 8% of patients; and CLDN18.2 expression is present in about 40% of patients. There is, of course, biomarker overlap. About 13% to 22% of CLDN18.2 patients are also PD-L1 positive. For patients with pMMR or microsatellite stable HER2-negative disease with PD-L1 expression greater than 1 and absence of CLDN18.2, the panel recommended a first-line therapy with fluoropyrimidine and platinum-based therapy in combination with immunotherapy. These recommendations stem from large phase 3 trials, and the agents approved in the United States are pembrolizumab, nivolumab, and tislelizumab. It has been shown that immunotherapy benefit is greater in patients with higher PD-L1 expression, and it is not possible to comment on the individual PD-L1 cutoff scores and sort of identify the optimal PD-L1 cutoff score that sort of balances benefits and harms. But what is recommended is that immunotherapy-based treatments can be offered in patients with a CPS score of greater than 1. With regard to the choice of immunotherapy agents, that is pembrolizumab, nivolumab, or tislelizumab, these agents are considered to have similar efficacy, and the selection of an agent could be based on dosing schedule, cost considerations, toxicity, and the method of administration. Typically, clinicians should avoid withholding the start of chemotherapy while awaiting biomarker testing, depending on the clinical scenario. Now, for patients with pMMR microsatellite stable disease that is HER2-negative with PD-L1 expression less than 1 and positive CLDN18.2 expression, zolbetuximab-based treatments or in combination with chemotherapy is recommended, and this is based on two global phase III randomized controlled trials, the GLOW and the SPOTLIGHT. And across both studies, the hazard ratio for the overall survival was 0.78, and similarly, there was also an improvement in progression-free survival favoring the zolbetuximab group compared to the chemotherapy group alone. An important note is that nausea, vomiting is commonly associated with zolbetuximab-based treatments, and the panel recommended prophylactic antiemetics, adjusting zolbetuximab infusion rates, pausing infusion temporarily, using non-prophylactic antiemetics, and hydration intravenously prior to discontinuation of zolbetuximab-based chemotherapy. So effective handling of the GI-related symptoms with zolbetuximab is recommended prior to discontinuation of therapy. Now, for patients with pMMR microsatellite stable HER2-negative gastric, GE junction adenocarcinoma with PD-L1 expression greater than 1 and CLDN18.2 positivity, the ones with the dual expression with CLDN18.2 as well as PD-L1 chemotherapy, the choice of therapy can be based on the degree of PD-L1 expression, the toxicity profile, the burden of symptoms, and the anticipated improvement in symptoms associated with response to treatment, the patient comorbidities, the prior medical and treatment history. So this decision needs to be made on a case-by-case basis, and these are some of the factors that we suggested that could potentially influence the choice of therapy. For patients with pMMR microsatellite stable disease that is HER2-negative and a PD-L1 expression less than 1 and an absence of CLDN18.2 expression, first-line therapy with fluoropyrimidine and platinum-based chemotherapy is recommended. So you can see we have segmented out patients based on PD-L1 expression, pMMR and microsatellite stable disease expression, and also based on CLDN expression. Brittany Harvey: Absolutely. And that first point you noted, I think is really important, that biomarker testing is really critical for treatment decision-making in this space. So then the next subgroup of patients that the panel looked at, Dr. Shah, what first-line therapy is recommended for patients with proficient mismatch repair, microsatellite stable, HER2-positive gastroesophageal adenocarcinoma? Dr. Manish Shah: So this was an update from a few years ago. So we have known for 15 years now that if you are HER2-positive, you should get trastuzumab plus chemotherapy. That was based on the ToGA trial. And the update now is based on a trial called KEYNOTE-811, where it examined the addition of pembrolizumab to trastuzumab and chemotherapy versus trastuzumab and chemotherapy, and there was a progression-free and overall survival benefit. And again, here, the biomarkers are important. If your CPS PD-L1 is less than 1, we would not recommend Pembrolizumab in that setting, so you would still get trastuzumab and chemotherapy. But if it is 1 or greater, the PD-L1 CPS score, then we do recommend pembrolizumab unless there is a contraindication to immunotherapy. The take-home message really is from the onset of diagnosis, please check your biomarkers. And I will just, it is worth repeating, it is important to check your PD-L1 status, HER2 status, mismatch repair status, and CLDN18.2 status. And then the optimal therapy, and it is outlined in the publication, is really biomarker-driven. We know that if we are able to hit the target that is overexpressed, we are going to have a better outcome. And Dr. Rajdev did mention where there is overlap, there can be a lack of data, and that is where we are with both PD-L1 positive and CLDN positive. Here we do have data in HER2-positive cases where if you are both HER2-positive and PD-L1 positive, you would combine trastuzumab and pembrolizumab for the best outcomes. Brittany Harvey: Understood. I really appreciate you detailing what is most important for each individual biomarker combination that patients may have. So then following that, Dr. Rajdev, what does the expert panel recommend for first-line treatment for patients with esophageal squamous cell carcinoma that is not amenable to definitive chemoradiation? Dr. Lakshmi Rajdev: There are three phase III randomized clinical trials that have influenced practice in patients with esophageal squamous cell carcinoma examining the benefit of immunotherapy in this patient population. The RATIONALE-306 was a randomized trial of tislelizumab plus chemotherapy with platinum and fluoropyrimidine or paclitaxel versus placebo with chemotherapy. And then you have the KEYNOTE-590, which compared pembrolizumab plus chemotherapy versus chemotherapy alone. And then you have CheckMate-648, which included comparisons of nivolumab plus chemotherapy versus nivolumab plus ipilimumab or chemotherapy. And the primary endpoints for these studies were overall survival, and they did look at subgroups with PD-L1 expression. They used TPS score greater than 1% in CheckMate-648 and PD-L1 CPS greater than 10 in KEYNOTE-590. The bottom line is that the overall hazard ratio for overall survival across this patient population was 0.72. So clearly, there is benefit in patients that express PD-L1 CPS greater than 1 for benefit for the addition of immunotherapy. Now, the benefit again in patients with a PD-L1 expression less than 1 remains limited, and so the panel has made a recommendation for using immunotherapy in combination with platinum-based chemotherapy in patients with a PD-L1 greater than 1. Again, we know that it is hard to make recommendations on what PD-L1 cutoffs are recommended in this patient population, meaning that should it be limited to patients with a PD-L1 of 1 to 4 or greater than 10? I think that the general consensus that has been gleaned from the data is that the higher the PD-L1 expression, the greater the benefit. I do want to comment on another option that is available in patients with squamous cell carcinoma compared to adenocarcinoma, and that is the combination of nivolumab and ipilimumab. Now, in CheckMate-648, nivolumab with ipilimumab was also recommended as a treatment option in patients that have a PD-L1 score of greater than 1. There was a survival benefit demonstrated with this combination compared to chemotherapy alone. And an important observation in this study is that, although there was a slightly increased rate in early death, but there was really no significant difference in PFS and OS compared to chemotherapy alone. Importantly, the treatment appeared to be pretty well tolerated by the study population. There was a notable difference in the objective response rate, which was 35% in the nivolumab plus ipilimumab group compared to patients receiving nivolumab and chemotherapy, where it was 53%. So superiority is, so the importance of chemotherapy in patients with esophageal squamous cell carcinoma is to be noted. However, there is no difference in overall survival and progression-free survival when using the combination of nivolumab and ipilimumab, and thus it affords a chemotherapy-free option for this patient population with esophageal squamous cell carcinoma and a CPS with a score of greater than 1. Brittany Harvey: Understood. I appreciate you reviewing the evidence underpinning those recommendations as well. So then the next patient population that the guideline panel addressed, what first-line therapy is recommended for patients with deficient mismatch repair, microsatellite instability-high, gastroesophageal adenocarcinoma or esophageal squamous cell carcinoma? Dr. Lakshmi Rajdev: The rate of MSI-high expression is about 3% to 7% across different studies. Now, the KEYNOTE-158 was a tumor-agnostic study in patients with non-colorectal cancers, and again, the problem with the MSI-high population, given that it is so rare, the numbers in the individual studies are fairly small. But consistent outcomes do emerge, indicating high response to immunotherapy. So in KEYNOTE-158, a response rate of about 46% was noted. The number of patients was small, it was about 24. In CheckMate-649, which is a study of chemotherapy plus or minus nivolumab in patients with advanced gastric adenocarcinoma, there was again a very small number of patients, and patients that were MSI-high or deficient MMR did experience substantial benefits with the addition of immunotherapy, with hazard ratios in the order of about 0.38. In KEYNOTE-062, again, it was a very small number of patients, again about 6% or so, and similar to CheckMate-649, a substantial benefit was noted in combination with chemotherapy, but also there were benefits noted with pembrolizumab alone. The RATIONALE-305 again was a study of tislelizumab in combination with chemotherapy and similarly showed benefits to the combination of chemotherapy plus immunotherapy in this patient population. I think that we are all aware of the dramatic benefits of immunotherapy in this particular subset of patients, deficient MMR MSI-high, and also we have seen in CheckMate-649 they did have a subset of patients that received nivolumab and ipilimumab. And in this patient population, they noted unstratified hazard ratio of 0.28. So I think that the overall consensus is that immunotherapy is a very important treatment modality in patients with deficient MMR MSI-high disease, given that a lot of the trials in gastroesophageal adenocarcinoma have utilized chemotherapy-based options, that is certainly a recommendation of the panel to use chemotherapy in combination with immunotherapy. However, on a case-by-case basis, the panel recommended immunotherapy alone as well, and given the high response rates noted in trials across different diseases as well as noted in this disease as well. Brittany Harvey: Certainly. And I appreciate you both for reviewing these first-line recommendations. So moving to later lines of therapy, Dr. Rajdev, what recommendations did the expert panel make for second or third-line therapy for gastroesophageal adenocarcinoma and esophageal squamous cell carcinoma? Dr. Lakshmi Rajdev: So, I think that the RAINBOW trial that investigated the utility of the addition of ramucirumab as second-line therapy has been around since 2014, and those results have led to the addition of ramucirumab to taxane-based therapy in the second-line setting. Based on the utilization of oxaliplatin and platinum-based therapy in the front-line setting, there may be patients that have an underlying neuropathy, and so we wanted to really include treatment options for this patient population so that an agent that is less neurotoxic could also be recommended in combination with ramucirumab. The RAMIRIS trial is one such trial where ramucirumab was combined with FOLFIRI, and it demonstrated benefit in combination with ramucirumab. So we have listed that as a potential treatment option for patients in the second-line setting who may have an underlying neuropathy or even for whatever reason that based on the toxicity profile, that needs to be the preferred option by a physician, that recommendation is new from the older guidelines that we have. With regard to the utility of PD-1 inhibitors, there really has been no benefit noted in the second-line setting with regard to overall survival or progression-free survival, so no recommendation is made for that option. I think an important study that has been recently presented is the DESTINY-Gastric04 trial, which really has been practice-changing and has led to the recommendation for trastuzumab deruxtecan in patients that have HER2-positive metastatic gastric or GE junction adenocarcinoma. Now, this is a phase III trial in patients who retained HER2-positive disease after progressing on front-line trastuzumab-based treatments, and the comparator for this trial was trastuzumab deruxtecan versus ramucirumab plus paclitaxel. There was significant improvement and progression-free survival in patients that received trastuzumab deruxtecan. The patients that were excluded from the trial are patients that have pulmonary problems, interstitial lung disease; that is one of the toxicities of this particular agent, and close monitoring and prompt initiation of therapy such as glucocorticoid treatment in patients who develop this toxicity was also highlighted by the panel. So to summarize, the new guidelines highlight the possibility of FOLFIRI plus ramucirumab as a second-line option and then trastuzumab deruxtecan as a later-line option in patients that still retain HER2 expression. And that is very important because the trial did retest patients whether they expressed HER2. As we know, in a substantial number of patients, there is downregulation of HER2, and there is emerging data that the benefit for subsequent HER2-directed therapies is best noted in patients that still retain HER2 expression. Brittany Harvey: Great. So as our listeners have heard, there are many recommendations and new treatment options for advanced gastroesophageal cancer. Dr. Shah, earlier you highlighted the importance of biomarker testing, but I would like to hear in your view, what is the importance of this guideline and how will it impact both clinicians and patients with gastroesophageal carcinoma? Dr. Manish Shah: So as we have discussed throughout this podcast, the treatment for gastroesophageal cancer, both adenocarcinoma and squamous cell cancer, is increasingly complex, increasingly biomarker-driven. And I think the value of the guideline is to place all of that into context. So it provides the data for why certain biomarkers are important, what therapies should be indicated. Not only that, but if you are able to review the guideline, it provides the details of each of these studies and summarizes them in a meta-analysis fashion to sort of give you the context, because sometimes the individual studies can be maybe a little bit discordant or confusing and the guideline attempts to harmonize all that. And then also, I think the tables are very, very interesting because they give you actual numbers in terms of how many patients over a thousand would this benefit or how many patients over a thousand would this cause harm in terms of nausea, vomiting, or other things like that. So it gives you context for helping clinicians and patients weigh the potential benefits of the novel treatment strategies against the potential adverse events. And then finally, the guideline does also provide an algorithm that you are able to follow based on the biomarkers, and those are in figures 4 and 5. So I think overall, it is a very comprehensive guideline. It intends to make more manageable a very complex subject, and you know, I really encourage our listeners to review it after listening to the podcast. Dr. Lakshmi Rajdev: If I can add to that, I think that what is also really good about the guidelines is there are quick summaries. So if someone is busy in the clinic, of course, there is the opportunity to review the data supporting the guidelines in great depth in the manuscript, but what is also really good is that there are good summaries. In the event that you are very busy, you can easily identify what the recommendations should be for that particular patient based on these summaries. Brittany Harvey: Absolutely. Listeners are encouraged to review the full guideline, including those tables and figures that may be more helpful when they are looking for something quick to look at in the clinic as well. So, as you both mentioned, there have been a number of recent practice-changing trials in this area. So I imagine there is still a lot of ongoing research as well. So Dr. Shah, what are the outstanding questions regarding treatment options for patients with locally advanced unresectable, advanced, or metastatic gastroesophageal carcinoma? Dr. Manish Shah: I think we touched upon it a little bit. The guidelines are based on the data available, and they are primarily examining one novel therapy with chemotherapy in a specific biomarker population. But as you know, the biomarkers are not either/or; you are not either CLDN18.2 positive or PD-L1 positive. A portion of patients could have dual biomarkers, and you know, I think that we are generating data on how to manage those patients. At the recent GI Symposium in January this year, the ILUSTRO trial was presented by Dr. Shitara, which looked at combining zolbetuximab and chemotherapy with immunotherapy for dual-positive biomarkers, and that is leading to a phase III study that has begun to enroll. So unanswered questions are: how do we manage dual-positive biomarkers? The other thing that was mentioned is that the current data for mismatch repair deficiency involve chemotherapy plus immunotherapy. Only squamous cell cancer is there a study with a positive non-chemotherapy kind of backbone, that is CheckMate-648 that Dr. Rajdev mentioned. As we move forward, it will be good to get data on non-chemotherapy options in certain biomarker-positive populations. And then finally, another update, which is likely to be practice-changing, is the HERIZON-GEA-01 study that looked at zanidatamab, which is another biparatopic antibody that targets HER2, and that is likely to change practice. And as that data gets published, we may look to even do a rapid update for the current immunotherapy and targeted therapy guideline that is just being published. Dr. Lakshmi Rajdev: So, if I can add to that, there are numerous ADCs that look very interesting. There are bispecific antibodies; in fact, the zanidatamab is a bispecific antibody showing improved activity in patients with HER2-positive disease. So I think there are studies from Asia looking at CLDN CAR T-based therapies. So, I think that there are a lot of novel agents and a lot of excitement in the field. We know that the bemarituzumab study, unfortunately, the FGFR2 inhibitor failed to demonstrate any benefit, but I think that there are other agents that are being explored, so there are newer targets, newer agents, ADCs, bispecifics that could potentially change the field in the future. Brittany Harvey: Yes, we will look forward to the data to address these unanswered questions and new agents and inform future guideline updates. So, I would like to thank you both for all of your work to review the evidence here and update this important guideline, and for your time today, Dr. Rajdev and Dr. Shah. Dr. Lakshmi Rajdev: Thank you. Dr. Manish Shah: Thank you. Brittany Harvey: And finally, thank you to all of our listeners for tuning in to the ASCO Guidelines podcast. To read the full guideline, go to www.asco.org/gastrointestinal-cancer-guidelines. You can also find many of our guidelines and interactive resources in the free ASCO Guidelines app, which is available in the Apple App Store or the Google Play Store. If you have enjoyed what you have heard today, please rate and review the podcast and be sure to subscribe so you never miss an episode. The purpose of this podcast is to educate and to inform. This is not a substitute for professional medical care and is not intended for use in the diagnosis or treatment of individual conditions. Guests on this podcast express their own opinions, experience, and conclusions. Guest statements on the podcast do not express the opinions of ASCO. The mention of any product, service, organization, activity, or therapy should not be construed as an ASCO endorsement.
In this powerful episode, we sit down with Dr. Joe Zundell — aka “Cancer Daddy” — for a wide-ranging conversation on cancer science, early detection, and what's actually moving the field forward. We cover: • Multi-cancer early detection (MCED) testing and the promise of liquid biopsies • Accuracy, limitations, and clinical decision-making • Metabolic vulnerabilities in cancer (Warburg effect, glutamine dependence) • Epigenetics and tumor biology • Immunotherapy, targeted therapies, and radiopharmaceuticals • Translational research and the bench-to-bedside gap • Drug resistance and evolutionary pressure in cancer treatment • Personalized risk reduction and prevention strategies We also get very personal in this episode — discussing loss, integrity in academia, career pivots, and what truly drives Dr. Zundell's mission in cancer research. This is an honest, science-first, and deeply human conversation about cancer, prevention, innovation, and responsibility in modern medicine. Coach Vinny Email: vinny@balancedbodies.io Instagram: vinnyrusso_balancedbodies Facebook: Vinny Russo Dr. Eryn Email: dr.eryn@balancedbodies.io Instagram: dr.eryn_balancedbodies Facebook: Eryn Stansfield Dr. Joe Zundell Email: drjoezundell@gmail.com Instagram: dr.joezundell LEGION 20% OFF CODE Go to https://legionathletics.com/ and use the code RUSSO for 20% off your order!
In this episode of Lung Cancer Considered, host Dr. Narjust Florez explores the evolving landscape of emerging molecular targets in NSCLC with Dr. Kelsey Pan and Rajat Thawani, live from the Targeted Therapies of Lung Cancer (TTLC) 2026 conference. The discussion highlights rare oncogenic drivers with a focus on clinical evidence, resistance mechanisms and trial design. The episode also addresses biomarker testing, the role of next-generation sequencing and liquid biopsy, and what the next five years may hold for precision treatment strategies in NSCLC. Guests: Kelsey Pan, MD, MPH Assistant Professor of Medicine Department of Hematology & Oncology, Thoracic Medical Oncology Section Emory University Winship Cancer Institute Rajat Thawani, MD Assistant Professor of Medicine Division of Hematology and Oncology Knight Cancer Institute, OHSU
In this podcast episode, Nilofer Azad, MD, FASCO, and Zev A. Wainberg, MD, discuss novel RAS-targeted therapies for pancreatic cancer, including the following: Optimal KRAS mutation testing Emerging multiselective RAS inhibitors Combination strategies Presenters: Nilofer Azad, MD, FASCO Professor of Oncology Associate Director of Clinical Research Sidney Kimmel Cancer Center at Johns Hopkins University Co-Leader, Developmental Therapeutics Clinical Trials Group Baltimore, Maryland Zev A. Wainberg, MD Professor of Medicine and Surgery Co-Director, GI Oncology Program UCLA School of Medicine Los Angeles, California Content based on an online CME program supported by an educational grant from Revolution Medicines, Inc. Link to full program: https://bit.ly/4avdRZK Get access to all our new podcasts by subscribing to the Decera Clinical Education Oncology Podcast on Apple Podcasts, YouTube Music, or Spotify. Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.
Drs. Dizon and Campos discuss how new antibody drug conjugates like trastuzumab deruxtecan are transforming treatment options for HER2+ gynecological cancers, showing promising results even in patients with low HER2 expression. They shared impressive clinical trial successes while emphasizing the importance of ongoing research into treatment sequencing and patient safety.
In today's episode, our discussion features Aditya Bardia, MD, MPH, FASCO. Dr Bardia is a professor in the Department of Medicine in the Division of Hematology/Oncology, the director of Translational Research Integration, and a member of Signal Transduction and Therapeutics at the UCLA Health Jonsson Comprehensive Cancer Center in Los Angeles, California.In our exclusive interview, Dr Bardia discussed key findings from the phase 3 lidERA Breast Cancer study (NCT04961996) showing the invasive disease–free survival superiority of giredestrant (GDC-9545) over standard endocrine therapy in patients with estrogen receptor–positive, HER2-negative early breast cancer. Our discussion also covered the ongoing phase 3 INAVO123 trial (NCT06790693), which is investigating inavolisib (Itovebi) plus CDK4/6 inhibitors and letrozole in patients with endocrine-sensitive, PIK3CA-mutated breast cancer. Dr Bardia also emphasized the importance of testing for ESR1 and PIK3CA mutations in order to better personalize treatment.
This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, and complete EBAC/CME information, and to apply for credit, please visit us at PeerView.com/PBT865. EBAC/CME credit will be available until 7 January 2027.From Poor Prognosis to Emerging Clinical Potential: A Visual Journey of Targeted Therapy Innovation in Extrapulmonary Neuroendocrine Carcinomas In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an independent medical educational grant from Boehringer Ingelheim Pharmaceuticals, Inc.Disclosure information is available at the beginning of the video presentation.
Drs. Coombs and Danilov explore how to optimally sequence covalent BTK inhibitors, non‑covalent BTK inhibitors (such as pirtobrutinib), and venetoclax-based regimens for relapsed CLL, emphasizing real-world data and emerging trial results. They highlight that treatment choices hinge on prior response depth and duration, tolerability, mutational profile, and the need to preserve future options and clinical trial eligibility.
Featuring perspectives from Dr Jaffer A Ajani, Dr Samuel J Klempner, Dr Rutika Mehta and Dr John Strickler, moderated by Dr Klempner, including the following topics: Introduction (0:00) HER2-Targeted Approaches for Advanced Gastroesophageal Cancers — Dr Ajani (2:02) Faculty Panel Discussion: Cases and Questions from the Community (14:13) Targeting Claudin 18.2 in Advanced Gastroesophageal Cancers — Dr Strickler (37:29) Faculty Panel Discussion: Cases and Questions from the Community (49:21) Optimal Incorporation of Immunotherapeutic Strategies into Treatment for Patients with Metastatic Gastroesophageal Tumors — Dr Mehta (1:09:56) Faculty Panel Discussion: Cases and Questions from the Community (1:22:02) Other Novel Agents and Strategies Under Evaluation for Advanced Gastroesophageal Cancers — Dr Klempner (1:44:23) CME information and select publications
© 2020-2026 Ivy Podcast Discovery LLC
